Symphogen Launches New Website and Marketing Materials
News Dec 21, 2005
Symphogen has recently launched a new website accompanied by several new factsheets detailing the company, technology and products.
Symphogen’s recombinant polyclonal antibody products are geared to the treatment of diseases caused by complex target antigens such as cancer, infectious diseases, transplantation rejection, and allergy.
The Company’s lead product, which combines 25 different recombinant anti-Rhesus D (RhD) antibodies for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN), is expected to enter the clinic in 2006.
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE